论文部分内容阅读
目的分析探讨FOLFRI治疗晚期胃癌40例的临床治疗效果。方法收集我院胃癌晚期患者80例,随机法分为对照组和实验组,每组各40例。对照组用传统方法FOLFOX方案治疗,实验组进行FOLFIRI方案治疗,分别在4个周期后评价两组疗效,进行比较分析。结果符合入组条件的病例共80例,其中试验组可评价疗效40例,总有效率为50.0%,对照组可评价疗效40例,总有效率为37.5%,两组疗效比较差异具有统计学意义(P<0.05);不良反应主要是恶心呕吐、骨髓抑制、迟发性腹泻等,两组不良反应比较差异具有统计学意义(P<0.05)。结论 FOLFIRI方案治疗晚期胃癌疗效肯定,不良反应可耐受,可供临床安全使用。
Objective To analyze the clinical efficacy of FOLFRI in treating 40 cases of advanced gastric cancer. Methods Eighty patients with advanced gastric cancer in our hospital were randomly divided into control group and experimental group, 40 cases in each group. The control group was treated with the traditional FOLFOX regimen. The experimental group was treated with the FOLFIRI regimen. After 4 cycles, the efficacy of the two groups was evaluated and compared. Results There were 80 cases that met the enrollment conditions, of which 40 cases could be evaluated in the trial group, the total effective rate was 50.0%, and 40 cases could be evaluated in the control group. The total effective rate was 37.5%. The difference in efficacy between the two groups was statistically significant. Significance (P<0.05); adverse reactions were mainly nausea and vomiting, bone marrow suppression, delayed diarrhea, etc. There was a statistically significant difference in adverse reactions between the two groups (P<0.05). Conclusion FOLFIRI regimen is effective in the treatment of advanced gastric cancer, and the adverse reactions can be tolerated and can be used safely in clinical practice.